New Approaches to Assessing and Treating Early-stage Colon and Rectal Cancer
Online CME Activity
This activity is published in the journal Clinical Cancer Research, Vol 13 (22 Suppl), pp 6853s-6856s, Nov 15, 2007: "New Approaches to Assessing and Treating Early-stage Colon and Rectal Cancer"
Up to 2 hours of AMA PRA Category 1 Credit™
Release date: November 2007 Valid through: November 2008
Course Material: CME Activity - PDF
Receiving CME Credit
To receive online CME credit for this activity, click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This activity is designed to meet the educational needs of medical and radiation oncologists, surgeons, pathologists and other medical professionals who assess and treat patients with colon and rectal cancers.
Educational Objectives
Following completion of this activity, participants should be able to discuss: current approaches and issues in diagnosing and defining stage II disease, how surgeons can contribute to preoperative staging and postsurgical assessment and treatment decisions, criteria for determining when adjuvant chemotherapy is appropriate in early-stage disease, and criteria for determining when biologic therapy is appropriate in early-stage disease.
Educational Need
Physicians and surgeons who assess, counsel and treat patients with colon and rectal cancers need to be aware of new approaches and multidisciplinary issues in sample dissection, staging, diagnosis, neoadjuvant and adjuvant treatment, and planned clinical trials. The manuscripts and edited discussion in this publication and the summary statement that comprises the basis of this CME activity, represent current recommendations and perspectives from a multidisciplinary faculty representing many of the leaders in this field.
Sponsorship and Accreditation
This enduring journal CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. (InforMEDical). InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
This program is supported by educational grants provided by: sanofi-aventis US, Hoffmann-La Roche, Amgen, Inc., Bristol-Myers Squibb/ ImClone and Genentech.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
The program faculty have reported the following financial relationships with commercial pharmaceutical, device and/or biotechnology companies: Robert W. Beart: Nothing to disclose. Al B. Benson: Amgen: consultant, research support; Bristol-Myers Squibb: consultant, research support; Genentech: consultant, research support; ImClone: consultant, research support; Pfizer: consultant, research support; Roche: consultant, research support; sanofi-aventis: consultant, research support. Anton J. Bilchik: Boston Scientific: consultant.; sanofi-aventis: consultant; Valleylab: consultant. Kenneth J. Chang: Nothing to disclose. Carolyn C. Compton: Nothing to disclose. Robert B. Diasio: Genentech: Speakers’ Bureau; Roche: Speakers’ Bureau; sanofi-aventis: Speakers’ Bureau. Axel F. Grothey: Amgen: consulting, honorarium; Genentech: consulting, honorarium; Roche: honorarium; sanofi-aventis: consulting, honorarium. Daniel G. Haller: Amgen: research support; Bristol-Myers Squibb: research support; Genentech: consultant, research support, Speakers’ Bureau; Novartis: consultant, research support; Pfizer: consultant, research support; Roche: consultant, research support; sanofi-aventis: consultant, research support, Speakers’ Bureau. Clifford Y. Ko: Nothing to disclose. Patrick M. Lynch: Nothing to disclose. Heidi Nelson: Nothing to disclose. Lee S. Rosen: Pfizer: research funding; sanofi-aventis: research funding. Michael J. Stamos: Nothing to disclose. Roderick R. Turner: Nothing to disclose. Christopher G. Willett: Genentech: conference speaker.